![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Twice Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in Genotype 1 HCV Liver Transplant Recipients: Interim Week 16 Calcineurin Inhibitor, Telaprevir, and Ribavirin Pharmacokinetics From the Prospective Multicenter REFRESH Study
|
|
|
Reported by Jules Levin
AASLD 2013 Nov 1-5 Wash DC
Robert J Fontana et al
![AASLD1.gif](../images/120413/120413-9/AASLD1.gif)
![AASLD2.gif](../images/120413/120413-9/AASLD2.gif)
![AASLD3.gif](../images/120413/120413-9/AASLD3.gif)
![AASLD4.gif](../images/120413/120413-9/AASLD4.gif)
![AASLD5.gif](../images/120413/120413-9/AASLD5.gif)
![AASLD6.gif](../images/120413/120413-9/AASLD6.gif)
![AASLD7.gif](../images/120413/120413-9/AASLD7.gif)
![AASLD8.gif](../images/120413/120413-9/AASLD8.gif)
![AASLD9.gif](../images/120413/120413-9/AASLD9.gif)
![AASLD10.gif](../images/120413/120413-9/AASLD10.gif)
![AASLD11.gif](../images/120413/120413-9/AASLD11.gif)
![AASLD12.gif](../images/120413/120413-9/AASLD12.gif)
![AASLD13.gif](../images/120413/120413-9/AASLD13.gif)
![AASLD14.gif](../images/120413/120413-9/AASLD14.gif)
![AASLD15.gif](../images/120413/120413-9/AASLD15.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|